Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FigHTN: Baxdrostat in Uncontrolled Hypertension and CKD
NCT05432167Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baxdrostat in hypertension (HTN) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in Mean Seated Systolic Blood Pressure at 26 weeks. Started Apr 2022; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05432167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05432167.